- Kamada signs an agreement with two undisclosed international pharmacies to commercialize three biosimilar product candidates in Israel. The two pharmaceutical companies will be responsible for the development, manufacturing, and supply of three products
- Following the approval from EMA and IMOH, the three products are expected to be launched in Israel b/w 2022 and 2024
- The collaboration will expand Kamada’s biosimilar portfolio in Israel which already includes six products previously licensed from Alvotech
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Globes English
The post Kamada to Commercialize Three Biosimilar Products in Israel first appeared on PharmaShots.